Tests biophoton devices as a treatment for type 2 diabetes
Tests whether light-based biophoton devices can treat type 2 diabetes in adults.
Key facts
- Who runs it
- First Institute of All Medicines
- Where
- Butler and Tampa, United StatesSee the 2 sites
- Trial code
- Registry title
- RCT to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
- Status
- Not yet recruiting
- People taking part
- 46 people, planned
- Started
- 8 Jun 2026
- Expected to end
- 15 Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Biophoton Generators
- Record updated
- 26 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with a doctor's diagnosis of type 2 diabetes, to test whether biophoton therapy can treat it.
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- Type 2 diabetes (DM2) diagnosed by a doctor, without major diseases.
- Earlier treatment
- People who are heavy users of Tesla BioHealing devices cannot join; the clinical team checks past device use.
Main reasons for not taking part
- Untreated psychiatric problems that would affect taking part
- Taking part in another investigational drug or device trial
- Heavy past use of Tesla BioHealing devices
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Willing and able to give informed consent for participation in the trial
- Is able and willing to comply with all trial requirements
- Male or female aged 18-70 years old without major diseases
- An adult clinically diagnosed with DM2
- Participants must not be heavy users of Tesla BioHealing devices; enrollment will be determined by the clinical team based on an evaluation of the participant's prior device usage
- Must be fluent in English
Who cannot take part
- Is participating in another investigational drug or device trial
- Untreated psychiatric disturbances that would affect trial participation as judged by research medical professionals
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Tesla BioHealing Medical Center in Butler-PAButler, United StatesContact: Audrey Ager, BSNo longer taking part
- Tesla BioHealing Medical Center in Butler-FLTampa, United StatesContact: Laura Poirier, BSNo longer taking part
About the trial
What the trial wants to find out
Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can treat diabetes.
Read full original descriptionShow less
Study Design This is a randomized, double-blind, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in treating diabetes. Approximately 46 volunteers will participate in the study.
Study Randomization The biostatistician will prepare a randomization schedule including a serial of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. This phase lasts for 4 weeks. At the end of Week 4, the active devices will replace the placebo. Both groups will be actively participating in the study for 2 months (8 weeks).
Other than the Informed Consent Form (ICF), all study information will be recorded by using the subject number.
The Principal Investigator, study physicians, study nurses, data-entry specialists, and biostatisticians, as well as the participants, will be blinded about who received which product during the first two weeks of study participation.
Study Enrollment Each potentially qualified volunteer will review the Informed Consent Form online (e-ICF) and Enrollment Criteria online (e-Criteria) first, then discuss the e-ICF and e-Criteria with the study team medical professional via telephone during the scheduled time. Each qualified volunteer will sign the e-ICF and send it to the Medical Office Coordinator. The study coordinator will assign the qualified volunteer a randomized subject number, then the volunteer will become a study participant.
The 2 groups in the trial
- PlaceboPlacebo, for comparison
The same size, shape, and weight of the devices without emitting biophotons will be provided and used during the first 4 weeks of the randomized study period.
Treatment: Biophoton Generators
- TreatmentTreatment being tested
Eight Tesla Biophotonizer-A will be packed in 4 sleeves and used during the study. The Placebo will be packed the same way without emitting biophotons.
Treatment: Biophoton Generators
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
- Plain-language title
- Tests biophoton devices as a treatment for type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07124208, who can take part
- Record updated
- 26 May 2026